SSA
TRVI icon

Schonfeld Strategic Advisors’s Trevi Therapeutics TRVI Stock Holding History

Schonfeld Strategic Advisors’s Portfolio TRVI Stock Details TRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-59,029
Closed -$194K – 1557
2020
Q1 		$194K Sell
59,029
-109,339
-65% -$497K 0.01% 919
2019
Q4 		$632K Sell
168,368
-442
-0.3% -$1.66K 0.02% 657
2019
Q3 		$760K Sell
168,810
-65,632
-28% -$357K 0.02% 537
2019
Q2 		$1.76M Buy
+234,442
New +$2.02M 0.06% 314

Other funds holding TRVI

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
TGHSA
TPG Group Holdings (SBS) Advisors Fort Worth, Texas $10.1B AUM 22.58% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
BBVA
Banco Bilbao Vizcaya Argentaria Madrid, Spain $14.3B AUM 26.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Canada Pension Plan Investment Board
Canada Pension Plan Investment Board Toronto Ontario, Ontario, Canada $155B AUM 29.93% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Schonfeld Strategic Advisors's TRVI Position: Q2 2020 in Review

Schonfeld Strategic Advisors sold out of Trevi Therapeutics (TRVI) in Q2 2020, closing a stake of 59,029 shares — an estimated $194K sold.

Schonfeld Strategic Advisors first reported a position in TRVI in Q2 2019 and held it in 4 quarters. The position peaked at $1.76M in Q2 2019. 16 funds tracked by Wall St. Rank hold TRVI as of Q2 2020.

  • Schonfeld Strategic Advisors reported no remaining Trevi Therapeutics position as of Q2 2020 after selling out during the quarter.
  • Schonfeld Strategic Advisors sold 59,029 Trevi Therapeutics shares in Q2 2020, an estimated $194K.
  • Schonfeld Strategic Advisors first reported a position in Trevi Therapeutics in Q2 2019 and held it in 4 quarters.
  • Schonfeld Strategic Advisors's Trevi Therapeutics position peaked at $1.76M in Q2 2019.
  • 16 funds tracked by Wall St. Rank held Trevi Therapeutics as of Q2 2020.

Based on Schonfeld Strategic Advisors's 13F filing for Q2 2020, filed 14 Aug 2020.